DosEdge

このアプリケーションは、登録した医師＆病院で使用するためのものです

This application when given appropriate data (Diagnosis Type, Weight, Product, Treatment Type, Bleed Type) for hemophilic patient gives information about the doses in IUs required for the patient.

This application when given appropriate data (Diagnosis Type, Weight, Product, Treatment Type, Bleed Type) for hemophilic patient gives information about the doses in IUs required for the patient.

This information is solely intended for the use of Registered Medical Practitioner and Hospital / Nurse only. This information should not be used or shared or distributed to any other person / party and should be strictly used by the intended parties for the intended purposes only. For more information, please refer to full Prescribing Information of corresponding products.

This material contains copyright protected information, content; the use of which is limited by law and this material cannot be reproduced, replicated, used or modified by any person for their own use or further distribution.

SHIRE and the Shire Logo are trademarks or registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affiliates.

ADVATE, HEMOFIL-M, IMMUNATE, RECOMBINATE, IMMUNINE, RIXUBIS, FEIBA and logos are trademarks of Baxalta Incorporated, a wholly owned, indirect subsidiary of Shire plc.

The application has been designed to offer convenient dosage calculation only for Anti-Hemophilic Factors (AHFs) and Bypassing agents manufactured by Baxalta Biosciences and registered in India. The healthcare practitioner is recommended to refer the full prescribing information for the specific product prior to the usage of the product.

Marketed in India by

Baxalta Bio Science India Pvt Ltd. (Now part of Shire)

6th Floor, Tower C, Building 8, DLF Cyber City

DLF Phase II

Gurgaon, Haryana - 122002 INDIA.

Tel: +91 124 4559100

For more information, please drop an email to medinfoAPAC@shire.com

www.shire.com C-APROM/IN//0030

For product safety or quality concerns or to report any side effects, please contact DrugSafety@Shire.com